PHARMACOGENETICS OF AROMATASE INHIBITORS (AIS) IN PATIENTS WITH METASTATIC BREAST CANCER

被引：0
|
作者：
Ferraldeschi, R. [1 ]
Arnedos, M. [2 ]
Hadfield, K. [3 ]
Ahern, R.
Drury, S. [4 ]
Roberts, S. [3 ]
Howell, A. [1 ]
Smith, I. [2 ]
Newman, W. [3 ]
Dowsett, M. [5 ]
机构：
[1] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[2] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England
[3] St Marys Hosp, Manchester M13 0JH, Lancs, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Royal Marsden NHS Trust, Dept Acad Biochem, London, England
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [1] Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer ( mBC) patients
    Singh, Neeraj
    Agrawal, Smita
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [2] Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients
    Arnedos, M.
    Ferraldeschi, R.
    A'Hern, R.
    Hadfield, K.
    Roberts, S.
    Drury, S.
    Howell, A.
    Evans, D. G.
    Wardley, A. M.
    Smith, I. E.
    Newman, W. G.
    Dowsett, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Aromatase inhibitors in metastatic breast cancer
    Buzdar, AU
    Plourde, PV
    Hortobagyi, GN
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (04) : 28 - 32
  • [4] Adherence to aromatase inhibitors (AIs) in Hispanic patients with early stage breast cancer
    Philipovskiy, Alexander
    Campbell, Aleli
    Heydarian, Rosalinda
    Lin, Krysta
    Nahleh, Zeina A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07)
  • [5] The impact of waist-to-hip ratio (WHR) on survival in metastatic breast cancer patients treated with aromatase inhibitors (AIs)
    Artac, M.
    Samur, M.
    Bozcuk, H.
    Afacan, B.
    Ozdogan, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] THE IMPACT OF LEPTIN AND ESTRADIOL LEVELS ON CLINICAL OUTCOMES IN METASTATIC BREAST CANCER (MBC) PATIENTS TREATED WITH AROMATASE INHIBITORS (AIS)
    Artac, M.
    Samur, M.
    Kiyici, A.
    Afacan, B.
    Ozdogan, M.
    Bozcuk, H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 71 - 71
  • [7] Aromatase inhibitors and metastatic breast cancer survival.
    Abrial, C
    Leheurteur, M
    Cabrespine, A
    Mouret-Reynier, MA
    Durando, X
    Ferrière, JP
    Kwiatkowski, F
    Penault-Llorca, F
    Curé, H
    Chollet, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 69S - 69S
  • [8] The role of aromatase inhibitors in the treatment of metastatic breast cancer
    Mouridsen, H
    Gershanovich, M
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (04) : 33 - 45
  • [9] Endothelial dysfunction in breast cancer survivors on aromatase inhibitors (AIs) over time
    Blaes, A. H.
    Petersen, A.
    Beckwith, H.
    Potter, D.
    Florea, N.
    Yee, D.
    Vogel, R.
    Duprez, D.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [10] Baseline bone mineral density testing among breast cancer patients prescribed aromatase inhibitors (AIs).
    Charlson, John A.
    Smith, Elizabeth
    Laud, Purushottam
    Smallwood, Alicia
    Neuner, Joan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345